Voyager Therapeutics Inc VYGR:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/07/21 EDT
4.21quote price arrow down-0.10 (-2.32%)
Volume
6,415
Close
4.31quote price arrow down-0.07 (-1.60%)
Volume
314,275
52 week range
4.21 - 14.62

...

Loading . . .
  • Open4.38
  • Day High4.47
  • Day Low4.21
  • Prev Close4.31
  • 52 Week High14.62
  • 52 Week High Date06/23/20
  • 52 Week Low4.21
  • 52 Week Low Date05/07/21

Key Stats

  • Market Cap162.62M
  • Shares Out37.73M
  • 10 Day Average Volume1.24M
  • Dividend-
  • Dividend Yield-
  • Beta1.10
  • YTD % Change-39.72

KEY STATS

  • Open4.38
  • Day High4.47
  • Day Low4.21
  • Prev Close4.31
  • 52 Week High14.62
  • 52 Week High Date06/23/20
  • 52 Week Low4.21
  • 52 Week Low Date05/07/21
  • Market Cap162.62M
  • Shares Out37.73M
  • 10 Day Average Volume1.24M
  • Dividend-
  • Dividend Yield-
  • Beta1.10
  • YTD % Change-39.72

RATIOS/PROFITABILITY

  • EPS (TTM)0.95
  • P/E (TTM)4.51
  • Fwd P/E (NTM)-1.57
  • EBITDA (MRQ)31.201M
  • ROE (MRQ)28.95%
  • Revenue (MRQ)171.13M
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)21.47%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date08/09/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Voyager Therapeutics Inc

There is no recent news for this security.

Profile

MORE
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company's pipeline consists of programs for CNS indications, including advanced Parkinson's disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington's disease; Friedreich's ataxia; frontotemporal dementia/Alzheimer's disease, and severe chronic pain. The...
G. Andre Turenne
President
Allison Dorval
Chief Financial Officer
Address
75 Sidney St
Cambridge, MA
02139-4134
United States